Bluesight, a Thoma Bravo-backed drug diversion detection company, acquired data privacy and security startup Protenus, CEO Kevin MacDonald tells Axios exclusively.
Why it matters: Bluesight made three acquisitions in 2024 after one in 2023 and "is going to be aggressively looking for opportunities in 2025," says Thoma Bravo partner Carl Press.
